maintenance saline IV fluids for hospitalized children at Sick Kids or in the literature. This will be the first prospective trial comparing hypotonic versus isotonic intravenous (IV) maintenance fluids in children. Additionally we will generate pilot data which will form the basis for an external grant proposal for a large scale randomized clinical trial to definitively examine the question of the most appropriate tonicity for paediatric IV maintenance solutions. Such a study would require a dichotomous outcome measure (dysnatremia: yes vs no). Given a baseline occurrence rate estimated at less than 10% in those receiving hypotonic fluids, over 1000 patients would be required. The impact and significance of our work is that it has the potential to guide the choice of IV maintenance fluids used in children internationally to decrease the morbidity and mortality currently seen as a result of dysnatremias in these children.
Hyponatremia, has become increasingly recognized as a cause of morbidity and mortality in hospitalized children. 1, 2, 3, 4, 5, 6 The main etiology of hyponatremia in these children has been attributed to the use of hypotonic maintenance IV fluids. 3, 5, 6, 7 The traditional practice of providing IV maintenance solutions containing 20-30 mmol/L of Na is based on "physiological needs" proposed by Holliday and Segar due to nausea, stress, pain, and surgical interventions, has confirmed that Holliday and Segar's recommendations are frequently inappropriately applied. The routine solution chosen for maintenance IV fluids in children varies widely amongst groups of physicians at the same hospital and between hospitals. The need for a controlled study to compare the outcomes using hypotonic and isotonic saline has been emphasized. 9, 11 To avoid the development of hyponatremia, it has been suggested that isotonic 0.9% NaCl/dextrose 5% should be the standard maintenance IV solution. 3, 5, 7, 9 The routine use of an isotonic maintenance fluid solution has not yet been studied, and concerns exist regarding the potential for hypernatremia and salt and water overload. Any patients requiring IV maintenance therapy having conditions/diseases not listed as excluded are eligible to be in this study. Examples include, but not limited to, pneumonia, bronchitis, asthma, sepsis, urinary tract infection, cellulites, osteomyelitis, feeding problems, aspiration, abdominal pain, and other miscellaneous conditions.
All children fitting the criteria outlined above will be identified from the Emergency Department and on inpatient wards by the clinical research coordinator in conjunction with the nursing staff on those units. Eligible patients will be identified by the study coordinator. For patients who present during the day, the coordinator will be contacted by ward staff. In order to capture patients who present after hours, the coordinator will review the list of patients who have been admitted from the Emergency Department on a daily basis. Patients who meet eligibility criteria will be approached by their responsible nurse or physician to discuss participation in this study. If they agree, one of the study investigators or a qualified designate will explain study requirements to the patient and/or their primary caregiver(s).
Consent will be obtained and children will be enrolled by one of the study investigators or by a qualified designate. We anticipate that the bulk of the study population will be enrolled in the ED and admitted to the Pediatric Medicine wards. The Emergency Department has 3000 admissions per year (or approximately 8.2 per day), therefore it is conservatively estimated that 1 patient/day will meet eligibility criteria and will agree to participate in this study. 
C.ii. Study design:
A randomized, double blind, controlled trial will be conducted comparing maintenance IV solutions with Na concentrations of 77 mmol/L (0.45% NaCl/dextrose 5%) and 154 mmol/L (0.9% NaCl/dextrose 5%) respectively. Blinding will be performed through the Pharmacy department which will randomly assigned a fluid type for each patient, stratifying subjects according to age (with a cut-off of 2.5 years) into strata A (patients less than or equal to 2.5 years of age) and Strata B (subjects with greater than 2.5 years of age) If serum potassium levels are 0.5 mmol/L or greater below the upper limit of normal for age (see Table   1 below), pharmacy will dispense the solution with 20mEq KCl/L of potassium included (either 0.45%NaCl with KCl 20mmol/L or 0.9%NaCl with KCl 20mmol/L, as randomized by Pharmacy), and the K result will be sent to the pharmacist at time of ordering study drug. Maintenance fluid volume will be calculated using the Holliday-Segar formula 8 (standard of care): Total daily fluid infusion equal to 100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg. This total will be divided by 24 to provide the hourly infusion rate. In patients taking oral fluids, the responsible team will be encouraged to decrease the IV rate accordingly (standard of care). e) Blood pressure will be monitored every morning by the study coordinator with the help of the patient's primary nurse.
C.iv. Study termination:
A data safety monitoring committee will review the data after 35 patients as it relates to safety. Each patient's study period will terminate at either 48 hours from enrollment (primary endpoint), or when any of the following criteria appear: a) Plasma Na >145 mmol/L or <135 mmol/L with change of ≥4 mmol/L from baseline Na.
b) Weight gain of >10% body weight compared with admission weight. c) Increased BP >20% diastolic or systolic compared with baseline on 3 consecutive readings over 1-2 hours and >95%ile for age.
After study termination, a patient's IV solution will be chosen based on the best standard of care by the primary physician.
At any time during the study, emergency unblinding can be requested by the responsible physician/delegate if there are serious clinical concerns (e.g. significant hypernatremia or hyponatremia) when the treatment of the patient will be different by knowing which IV study 
Sample size adjustments:
As there are multiple reasons why data may not be available (e.g. discharge prior to 48 hours, parental desire), we will estimate a 25% loss to follow-up, withdrawals, and missing data. Thus the final sample size will be 110.
C.vi. Data Analyses:
All analyses will be undertaken by the intention to treat principle, except for adverse events, which will use the "as treated" principle.
Baseline variables: Baseline characteristics such as age at randomization, weight, and serum chemistry results will be compared between randomization groups using descriptive statistics.
Frequency counts and percentages will be given for discrete variables, and means, medians, standard deviations and interquartile ranges for continuous variables. Baseline characteristics will be analyzed to determine if there is a need to adjust for any significant differences between the study groups.
Outcome variables: All statistical tests will be two-sided and will be conducted using the SAS system. The primary outcome, will be analyzed utilizing a 2-sample-t-test. Linear regression 
D. Adverse Events and Quality Assurance
Keeping in mind the outcome measures for this study, expected or potential risks/adverse events as a result of participation include dysnatremia, edema (weight gain), hypervolemia (fluid retention), and/or increase in blood pressure.
D.1 Definitions:
An adverse event is any new, undesirable medical occurrence or change (worsening) of an existing condition in a subject that occurs during treatment (through completion of the end-of-study procedures), whether or not considered to be product related.
Therefore, adverse events are treatment emergent signs or symptoms. In general, abnormal laboratory findings that are collected elsewhere on case report forms should not be recorded as adverse events; however, any associated clinical events should be reported as adverse events.
Thus, only abnormal laboratory values that are associated with clinical sequelae should be recorded as adverse events.
A serious adverse event is defined by regulatory agencies as one that suggests a significant hazard or side effect, regardless of the investigator's opinion on the relationship to study drug.
This includes, but may not be limited to, any event that (at any dose):
 is fatal  is life-threatening (places the subject at immediate risk of death)
 requires hospitalization or prolongation of existing hospitalization  results in persistent or significant disability/incapacity
